$JAZZ
Jazz Pharmaceuticals PLC Stock $jazz

$jazz Overview Financials Valuation SEC Filings Company Website

2017 Q4 Form 10-Q Financial Statement

#000123252417000179 Filed on November 07, 2017

Income Statement

Concept	2017 Q4	2017 Q3	2016 Q3
Revenue	$436.4M	$411.9M	$374.2M
YoY Change	10.03%	10.07%	9.77%
Cost Of Revenue	$25.20M	$31.20M	$24.30M
YoY Change	-25.22%	28.4%	-14.44%
Gross Profit	$404.8M	$376.8M	$347.3M
YoY Change	12.78%	8.48%	11.9%
Gross Profit Margin	92.77%	91.48%	92.82%
Selling, General & Admin	$143.0M	$124.5M	$124.4M
YoY Change	13.85%	0.12%	19.53%
% of Gross Profit	35.32%	33.05%	35.81%
Research & Development	$74.00M	$47.36M	$47.80M
YoY Change	67.42%	-0.91%	-5.88%
% of Gross Profit	18.28%	12.57%	13.76%
Depreciation & Amortization	$56.70M	$50.40M	$29.60M
YoY Change	90.27%	70.27%	3.14%
% of Gross Profit	14.01%	13.38%	8.52%
Operating Expenses	$270.0M	$325.4M	$237.9M
YoY Change	37.83%	36.76%	13.66%
Operating Profit	$134.8M	$86.45M	$136.3M
YoY Change	-17.3%	-36.55%	3.59%
Interest Expense	-$22.70M	-$19.19M	-$18.50M
YoY Change	56.55%	3.75%	46.23%
% of Operating Profit	-16.83%	-22.2%	-13.58%
Other Income/Expense, Net			-$749.0K
YoY Change			-23.34%
Pretax Income	$118.6M	$65.04M	$116.4M
YoY Change	-21.46%	-44.11%	-1.3%
Income Tax	$41.40M	$1.239M	$26.44M
% Of Pretax Income	34.91%	1.91%	22.72%
Net Earnings	$232.2M	$63.53M	$89.83M
YoY Change	99.0%	-29.28%	2.12%
Net Earnings / Revenue	53.21%	15.42%	24.01%
Basic Earnings Per Share	$3.87	$1.06	$1.49
Diluted Earnings Per Share	$3.79	$1.03	$1.45
COMMON SHARES
Basic Shares Outstanding	59.95M shares	60.11M shares	60.44M shares
Diluted Shares Outstanding		61.44M shares	61.80M shares

Balance Sheet

Concept	2017 Q4	2017 Q3	2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$601.0M	$452.6M	$426.0M
YoY Change	41.08%	6.24%	-57.35%
Cash & Equivalents	$386.0M	$252.6M	$366.6M
Short-Term Investments	$215.0M	$200.0M	$59.40M
Other Short-Term Assets	$76.69M	$49.12M	$24.52M
YoY Change	161.64%	100.35%	29.25%
Inventory	$43.25M	$41.34M	$32.35M
Prepaid Expenses	$23.18M	$29.25M	$23.30M
Receivables	$224.1M	$258.6M	$238.1M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$968.3M	$830.9M	$744.2M
YoY Change	29.44%	11.65%	-43.4%
LONG-TERM ASSETS
Property, Plant & Equipment	$170.1M	$159.4M	$99.90M
YoY Change	58.23%	59.55%	19.71%
Goodwill	$947.5M	$941.4M	$928.0M
YoY Change	6.01%	1.45%	38.71%
Intangibles	$2.979B	$3.019B	$3.110B
YoY Change	-1.09%	-2.94%	144.77%
Long-Term Investments
YoY Change
Other Assets	$16.42M	$16.42M	$37.76M
YoY Change	16.78%	-56.52%	48.72%
Total Long-Term Assets	$4.155B	$4.168B	$4.186B
YoY Change	2.55%	-0.44%	94.77%
TOTAL ASSETS
Total Short-Term Assets	$968.3M	$830.9M	$744.2M
Total Long-Term Assets	$4.155B	$4.168B	$4.186B
Total Assets	$5.124B	$4.999B	$4.931B
YoY Change	6.74%	1.39%	42.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$24.37M	$29.97M	$17.63M
YoY Change	8.71%	70.04%	-39.48%
Accrued Expenses	$198.8M	$179.9M	$172.4M
YoY Change	2.85%	4.33%	3.63%
Deferred Revenue	$8.618M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$40.61M	$36.09M	$36.09M
YoY Change	12.5%	0.0%	-69.3%
Total Short-Term Liabilities	$293.9M	$268.2M	$232.9M
YoY Change	14.2%	15.17%	-31.55%
LONG-TERM LIABILITIES
Long-Term Debt	$1.540B	$1.544B	$2.147B
YoY Change	-22.73%	-28.11%	83.21%
Other Long-Term Liabilities	$176.6M	$158.5M	$106.1M
YoY Change	56.82%	49.38%	77.82%
Total Long-Term Liabilities	$1.717B	$1.702B	$2.253B
YoY Change	-18.47%	-24.46%	82.95%
TOTAL LIABILITIES
Total Short-Term Liabilities	$293.9M	$268.2M	$232.9M
Total Long-Term Liabilities	$1.717B	$1.702B	$2.253B
Total Liabilities	$2.011B	$1.970B	$2.486B
YoY Change	-14.92%	-20.75%	58.17%
SHAREHOLDERS EQUITY
Retained Earnings	$918.0M	$728.1M	$315.4M
YoY Change	73.56%	130.85%	21.23%
Common Stock	$1.935B	$1.900B	$1.635B
YoY Change	16.23%	16.15%	6.61%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.713B	$2.469B	$1.831B
YoY Change
Total Liabilities & Shareholders Equity	$5.124B	$4.999B	$4.931B
YoY Change	6.74%	1.39%	42.33%

Cashflow Statement

Concept	2017 Q4	2017 Q3	2016 Q3
OPERATING ACTIVITIES
Net Income	$232.2M	$63.53M	$89.83M
YoY Change	99.0%	-29.28%	2.12%
Depreciation, Depletion And Amortization	$56.70M	$50.40M	$29.60M
YoY Change	90.27%	70.27%	3.14%
Cash From Operating Activities	$204.6M	$188.9M	$133.0M
YoY Change	13.23%	42.03%	-24.04%
INVESTING ACTIVITIES
Capital Expenditures	-$16.90M	-$83.40M	-$17.40M
YoY Change	1308.33%	379.31%	234.62%
Acquisitions
YoY Change
Other Investing Activities	-$15.00M	-$120.0M	-$1.514B
YoY Change	2400.0%	-92.07%
Cash From Investing Activities	-$31.90M	-$203.4M	-$1.531B
YoY Change	1578.95%	-86.71%	29342.31%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-40.00M	27.10M	895.2M
YoY Change	-76.74%	-96.97%	-1047.3%
NET CHANGE
Cash From Operating Activities	204.6M	188.9M	133.0M
Cash From Investing Activities	-31.90M	-203.4M	-1.531B
Cash From Financing Activities	-40.00M	27.10M	895.2M
Net Change In Cash	132.7M	12.60M	-502.8M
YoY Change	1851.47%	-102.51%	-766.84%
FREE CASH FLOW
Cash From Operating Activities	$204.6M	$188.9M	$133.0M
Capital Expenditures	-$16.90M	-$83.40M	-$17.40M
Free Cash Flow	$221.5M	$272.3M	$150.4M
YoY Change	21.77%	81.05%	-16.58%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Period End Date DocumentPeriodEndDate	2017-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001232524
CY2017Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	59950496	shares
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Jazz Pharmaceuticals plc
	dei	Trading Symbol TradingSymbol	JAZZ
CY2016Q4	jazz	Accrued Clinical Trial Liability AccruedClinicalTrialLiability	10139000	USD
CY2017Q3	jazz	Accrued Clinical Trial Liability AccruedClinicalTrialLiability	2657000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
CY2016Q4	jazz	Accrued Construction In Progress AccruedConstructionInProgress	1597000	USD
CY2017Q3	jazz	Accrued Construction In Progress AccruedConstructionInProgress	5488000	USD
CY2016Q4	jazz	Accrued Contract Termination Fees Current AccruedContractTerminationFeesCurrent	11612000	USD
CY2017Q3	jazz	Accrued Contract Termination Fees Current AccruedContractTerminationFeesCurrent	0	USD
CY2016Q4	jazz	Accrued Interest AccruedInterest	5179000	USD
CY2017Q3	jazz	Accrued Interest AccruedInterest	2347000	USD
CY2016Q4	jazz	Accrued Inventory Related Liabilities AccruedInventoryRelatedLiabilities	3350000	USD
CY2017Q3	jazz	Accrued Inventory Related Liabilities AccruedInventoryRelatedLiabilities	3843000	USD
CY2016Q4	jazz	Accrued Rebates And Other Sales Deductions AccruedRebatesAndOtherSalesDeductions	72344000	USD
CY2017Q3	jazz	Accrued Rebates And Other Sales Deductions AccruedRebatesAndOtherSalesDeductions	76930000	USD
CY2016Q4	jazz	Capital Redemption Reserve CapitalRedemptionReserve	472000	USD
CY2017Q3	jazz	Capital Redemption Reserve CapitalRedemptionReserve	472000	USD
CY2017Q3	jazz	Collaboration Agreement Right To Co Commercialize Number Of Products CollaborationAgreementRightToCoCommercializeNumberOfProducts	1	product
	jazz	Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment	71730000	USD
CY2017Q3	jazz	Collaboration Agreement Right To Co Commercialize Under Certain Limited Circumstances Number Of Products CollaborationAgreementRightToCoCommercializeUnderCertainLimitedCircumstancesNumberOfProducts	2	product
CY2017Q3	jazz	Collaborative Arrangement Development Funding Amount CollaborativeArrangementDevelopmentFundingAmount	100000000	USD
CY2017Q3	jazz	Collaborative Arrangements Development Funding Term CollaborativeArrangementsDevelopmentFundingTerm	P7Y
CY2017Q3	jazz	Collaborative Arrangements Numberof Programs Under Agreement CollaborativeArrangementsNumberofProgramsUnderAgreement	3	program
CY2016Q3	jazz	Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment	24311000	USD
CY2017Q3	jazz	Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment	31203000	USD
	jazz	Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment	84940000	USD
CY2016Q3	jazz	Gain Losson Extinguishmentand Modificationof Debt GainLossonExtinguishmentandModificationofDebt	-638000	USD
	jazz	Gain Losson Extinguishmentand Modificationof Debt GainLossonExtinguishmentandModificationofDebt	-638000	USD
CY2017Q3	jazz	Gain Losson Extinguishmentand Modificationof Debt GainLossonExtinguishmentandModificationofDebt	0	USD
	jazz	Gain Losson Extinguishmentand Modificationof Debt GainLossonExtinguishmentandModificationofDebt	0	USD
CY2016Q4	jazz	Nonvoting Euro Deferred Shares NonvotingEuroDeferredShares	55000	USD
CY2017Q3	jazz	Nonvoting Euro Deferred Shares NonvotingEuroDeferredShares	55000	USD
CY2016Q4	jazz	Number Of Customers With Significant Accounts Receivable Balance NumberOfCustomersWithSignificantAccountsReceivableBalance	5	Customer
CY2017Q3	jazz	Number Of Customers With Significant Accounts Receivable Balance NumberOfCustomersWithSignificantAccountsReceivableBalance	5	Customer
CY2017Q3	jazz	Paymentsto Acquire In Process Researchand Development Other Than Through Business Combination PaymentstoAcquireInProcessResearchandDevelopmentOtherThanThroughBusinessCombination	75000000	USD
	jazz	Paymentsto Acquire In Process Researchand Development Other Than Through Business Combination PaymentstoAcquireInProcessResearchandDevelopmentOtherThanThroughBusinessCombination	23750000	USD
	jazz	Paymentsto Acquire In Process Researchand Development Other Than Through Business Combination PaymentstoAcquireInProcessResearchandDevelopmentOtherThanThroughBusinessCombination	77000000	USD
	jazz	Provision For Losses On Accounts Receivable And Inventory ProvisionForLossesOnAccountsReceivableAndInventory	1764000	USD
	jazz	Provision For Losses On Accounts Receivable And Inventory ProvisionForLossesOnAccountsReceivableAndInventory	1825000	USD
CY2016Q3	jazz	Royalties And Contract Revenues RoyaltiesAndContractRevenues	2560000	USD
	jazz	Royalties And Contract Revenues RoyaltiesAndContractRevenues	6705000	USD
CY2017Q3	jazz	Royalties And Contract Revenues RoyaltiesAndContractRevenues	3884000	USD
	jazz	Royalties And Contract Revenues RoyaltiesAndContractRevenues	10990000	USD
CY2016Q4	jazz	Sales Return Reserve SalesReturnReserve	4366000	USD
CY2017Q3	jazz	Sales Return Reserve SalesReturnReserve	3470000	USD
	jazz	Stock Issued During Period Employee Plansand Warrants Exercises StockIssuedDuringPeriodEmployeePlansandWarrantsExercises	17951000	USD
	jazz	Stock Issued During Period Employee Plansand Warrants Exercises StockIssuedDuringPeriodEmployeePlansandWarrantsExercises	22793000	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	22415000	USD
CY2017Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	29972000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	234244000	USD
CY2017Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	258616000	USD
CY2016Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	43363000	USD
CY2017Q3	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	46672000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	193268000	USD
CY2017Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	179890000	USD
CY2016Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	3924000	USD
CY2017Q3	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	2384000	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4596000	USD
CY2017Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3244000	USD
CY2016Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	11643000	USD
CY2017Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	11309000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	32142000	USD
CY2017Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	40454000	USD
CY2017Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1899628000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-317333000	USD
CY2017Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-158987000	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1665232000	USD
	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	20595000	USD
	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	17909000	USD
	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	149767000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	75176000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	79745000	USD
CY2016Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	24874000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	74490000	USD
CY2017Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	27126000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	79579000	USD
CY2016Q3	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	16388000	USD
	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	50149000	USD
CY2017Q3	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	20772000	USD
	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	55763000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	16418000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	19234000	USD
CY2016Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	26453000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	75832000	USD
CY2017Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	47313000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	99164000	USD
CY2016Q4	us-gaap	Assets Assets	4800227000	USD
CY2017Q3	us-gaap	Assets Assets	4999024000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	748069000	USD
CY2017Q3	us-gaap	Assets Current AssetsCurrent	830944000	USD
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	425963000	USD
CY2017Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	452615000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2017Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2017Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	425963000	USD
CY2017Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	452615000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	988785000	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	366567000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	365963000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	252615000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-622218000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-113348000	USD
	us-gaap	Cash Flow Hedge Gain Loss To Be Reclassified Within Twelve Months CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths	-1200000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	6000	USD
CY2017Q3	us-gaap	Common Stock Value CommonStockValue	6000	USD
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	104440000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	312238000	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	114788000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	413987000	USD
CY2017Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1835781000	USD
CY2016Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	9737000	USD
CY2017Q3	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	8149000	USD
CY2016Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	15060000	USD
CY2017Q3	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	23662000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-29273000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-53359000	USD
CY2016Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	556733000	USD
CY2017Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	540964000	USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1123000	USD
CY2017Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	8618000	USD
CY2016Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2601000	USD
CY2017Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	18270000	USD
	us-gaap	Depreciation Depreciation	8165000	USD
	us-gaap	Depreciation Depreciation	9288000	USD
CY2017Q3	us-gaap	Derivative Asset Fair Value Gross Asset Including Not Subject To Master Netting Arrangement DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement	12325000	USD
CY2017Q3	us-gaap	Derivative Liability Fair Value Gross Liability Including Not Subject To Master Netting Arrangement DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement	1613000	USD
CY2016Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.49
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.62
CY2017Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.06
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.26
CY2016Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.45
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.51
CY2017Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.03
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.17
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	2350000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	4323000	USD
CY2016Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.227
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.265
CY2017Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.019
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.205
CY2016Q3	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	8486000	USD
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	24341000	USD
CY2017Q3	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	6354000	USD
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	23816000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	421687000	USD
CY2017Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	519944000	USD
CY2017Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	1991859000	USD
CY2017Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	52966000	USD
CY2017Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	204609000	USD
CY2017Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	205644000	USD
CY2017Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	208595000	USD
CY2017Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	208830000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1491768000	USD
CY2017Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	3392447000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1070081000	USD
CY2017Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2872503000	USD
CY2016Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-749000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1568000	USD
CY2017Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-2224000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-9115000	USD
CY2017Q3	us-gaap	Gain Loss On Cash Flow Hedge Ineffectiveness Net GainLossOnCashFlowHedgeIneffectivenessNet	0	USD
	us-gaap	Gain Loss On Cash Flow Hedge Ineffectiveness Net GainLossOnCashFlowHedgeIneffectivenessNet	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-3000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-360000	USD
CY2016Q4	us-gaap	Goodwill Goodwill	893810000	USD
CY2017Q3	us-gaap	Goodwill Goodwill	941428000	USD
	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	47618000	USD
CY2016Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	116368000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	381133000	USD
CY2017Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	65038000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	322192000	USD
CY2016Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-103000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-103000	USD
CY2017Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-273000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-637000	USD
CY2016Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	26437000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100888000	USD
CY2017Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1239000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	65914000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-4288000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	6130000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	28274000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	22273000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	3323000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	8495000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-7792000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-23583000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-682000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	23163000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	14117000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	7132000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-297000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1825000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	18352000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	12931000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	8512000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	10590000	USD
CY2016Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1358000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1458000	shares
CY2017Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1328000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1330000	shares
CY2016Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	3433688000	USD
CY2017Q3	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	3538979000	USD
CY2016Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3012001000	USD
CY2017Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3019035000	USD
CY2016Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-18498000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-42811000	USD
CY2017Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-19192000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-56330000	USD
CY2016Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	13815000	USD
CY2017Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	18698000	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	34051000	USD
CY2017Q3	us-gaap	Inventory Net InventoryNet	41344000	USD
CY2016Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1547000	USD
CY2017Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2681000	USD
CY2016Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	18689000	USD
CY2017Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	19965000	USD
CY2016Q4	us-gaap	Investments Investments	60000000	USD
CY2017Q3	us-gaap	Investments Investments	200000000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4800227000	USD
CY2017Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4999024000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	257406000	USD
CY2017Q3	us-gaap	Liabilities Current LiabilitiesCurrent	268177000	USD
CY2016Q4	us-gaap	Long Term Debt LongTermDebt	2029625000	USD
CY2017Q3	us-gaap	Long Term Debt LongTermDebt	1579913000	USD
CY2016Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	36094000	USD
CY2017Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	36094000	USD
CY2017Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	575000000	USD
CY2017Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	1075801000	USD
CY2017Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	76699000	USD
CY2017Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	58652000	USD
CY2017Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	40606000	USD
CY2017Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	9023000	USD
CY2016Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1993531000	USD
CY2017Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1543819000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	713032000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-369127000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1749296000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-237072000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	411696000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	488528000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	89828000	USD
	us-gaap	Net Income Loss NetIncomeLoss	280142000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	63526000	USD
	us-gaap	Net Income Loss NetIncomeLoss	255641000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
	us-gaap	Oci Before Reclassifications Net Of Tax Attributable To Parent OciBeforeReclassificationsNetOfTaxAttributableToParent	157068000	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	237928000	USD
	us-gaap	Operating Expenses OperatingExpenses	665202000	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	325401000	USD
	us-gaap	Operating Expenses OperatingExpenses	794657000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	136253000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	426150000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	86454000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	387637000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	243401000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	19166000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	19127000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	16885000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	15811000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	165797000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	6615000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	21155000	USD
CY2017Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	21546000	USD
CY2016Q4	us-gaap	Other Assets Current OtherAssetsCurrent	29310000	USD
CY2017Q3	us-gaap	Other Assets Current OtherAssetsCurrent	49120000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	14060000	USD
CY2017Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	16420000	USD
CY2016Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	14612000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	32096000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	50870000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	159302000	USD
CY2016Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	14612000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	32096000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	51262000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	158346000	USD
CY2016Q3	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	0	USD
CY2017Q3	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	392000	USD
	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-956000	USD
CY2016Q3	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax	0	USD
	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax	0	USD
CY2017Q3	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax	56000	USD
	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax	-137000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	112617000	USD
CY2017Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	158497000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1460000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	56425000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	20595000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	17909000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	1502443000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-14480000	USD
CY2016Q4	us-gaap	Other Short Term Investments OtherShortTermInvestments	60000000	USD
CY2017Q3	us-gaap	Other Short Term Investments OtherShortTermInvestments	200000000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	259819000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	150000000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	75904000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	290000000	USD
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	8410000	USD
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	20072000	USD
CY2016Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	24501000	USD
CY2017Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	29249000	USD
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	994777000	USD
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	559484000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	17951000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	22793000	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	11211000	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	150000000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	139632000	USD
CY2017Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	199840000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	107490000	USD
CY2017Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	159386000	USD
	us-gaap	Reclassification From Aoci Current Period Net Of Tax Attributable To Parent ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent	-1278000	USD
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0	USD
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	850000000	USD
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	19282000	USD
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	27070000	USD
CY2016Q3	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	15000000	USD
	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	23750000	USD
CY2017Q3	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	75000000	USD
	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	77000000	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	47796000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	118139000	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	47362000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	132447000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	528907000	USD
CY2017Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	728123000	USD
CY2016Q3	us-gaap	Revenues Revenues	374181000	USD
	us-gaap	Revenues Revenues	1091352000	USD
CY2017Q3	us-gaap	Revenues Revenues	411855000	USD
	us-gaap	Revenues Revenues	1182294000	USD
CY2016Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	371621000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1084647000	USD
CY2017Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	407971000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1171304000	USD
CY2016Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	124368000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	375751000	USD
CY2017Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	124523000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	401106000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	74490000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	79579000	USD
	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	259819000	USD
	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	56425000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	1706333000	USD
CY2016Q3	us-gaap	Stockholders Equity StockholdersEquity	1831284000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	1877339000	USD
CY2017Q3	us-gaap	Stockholders Equity StockholdersEquity	2469297000	USD
CY2016Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	4506000	USD
CY2017Q3	us-gaap	Taxes Payable Current TaxesPayableCurrent	13603000	USD
CY2017Q3	us-gaap	Unrecorded Unconditional Purchase Obligation Balance On First Anniversary UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary	43200000	USD
CY2016Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61795000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	62150000	shares
CY2017Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61436000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61360000	shares
CY2016Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60437000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60692000	shares
CY2017Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60108000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60030000	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font></div><div style="line-height:120%;padding-top:18px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Risk</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject us to concentrations of credit risk consist of cash, cash equivalents, investments and derivative contracts. Our investment policy permits investments in U.S. federal government and federal agency securities, corporate bonds or commercial paper issued by U.S. corporations, money market instruments, certain qualifying money market mutual funds, certain repurchase agreements, and tax-exempt obligations of U.S. states, agencies and municipalities and places restrictions on credit ratings, maturities, and concentration by type and issuer. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and investments to the extent recorded on the balance sheet.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We manage our foreign currency transaction risk and interest rate risk within specified guidelines through the use of derivatives. All of our derivative instruments are utilized for risk management purposes, and we do not use derivatives for speculative trading purposes. As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">, we had foreign exchange forward contracts with notional amounts totaling </font><font style="font-family:inherit;font-size:10pt;">$330.6 million</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the asset fair value of outstanding foreign exchange forward contracts was </font><font style="font-family:inherit;font-size:10pt;">$11.8 million</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">, we had interest rate swap contracts with notional amounts totaling </font><font style="font-family:inherit;font-size:10pt;">$300.0 million</font><font style="font-family:inherit;font-size:10pt;">. These outstanding interest rate swap contracts had a net liability fair value of </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">. The counterparties to these contracts are large multinational commercial banks, and we believe the risk of nonperformance is not material.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are also subject to credit risk from our accounts receivable related to our product sales. We monitor our exposure within accounts receivable and record a reserve against uncollectible accounts receivable as necessary. We extend credit to pharmaceutical wholesale distributors and specialty pharmaceutical distribution companies, primarily in the U.S., and to other international distributors and hospitals. Customer creditworthiness is monitored and collateral is not required. We monitor deteriorating economic conditions in certain European countries which may result in variability of the timing of cash receipts and an increase in the average length of time that it takes to collect accounts receivable outstanding.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001232524-17-000179-index-headers.html	Edgar Link	pending
0001232524-17-000179-index.html	Edgar Link	pending
0001232524-17-000179.txt	Edgar Link	pending
0001232524-17-000179-xbrl.zip	Edgar Link	pending
a3181portersiteplana01.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
jazz-20170930.xml	Edgar Link	completed
jazz-20170930.xsd	Edgar Link	pending
jazz-20170930_cal.xml	Edgar Link	unprocessable
jazz-20170930_def.xml	Edgar Link	unprocessable
jazz-20170930_lab.xml	Edgar Link	unprocessable
jazz-20170930_pre.xml	Edgar Link	unprocessable
jazz2017q3doc.htm	Edgar Link	pending
jazzq32017ex102.htm	Edgar Link	pending
jazzq32017ex311.htm	Edgar Link	pending
jazzq32017ex312.htm	Edgar Link	pending
jazzq32017ex321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$JAZZ
Jazz Pharmaceuticals PLC Stock $jazz

2017 Q4 Form 10-Q Financial Statement

#000123252417000179 Filed on November 07, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$JAZZ Jazz Pharmaceuticals PLC Stock $jazz

2017 Q4 Form 10-Q Financial Statement

#000123252417000179 Filed on November 07, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$JAZZ
Jazz Pharmaceuticals PLC Stock $jazz